Live Attenuated Influenza Vaccine (Fluenz™): a Guide to Its Use in the Prevention of Seasonal Influenza in Children in the EU

Overview

Journal Paediatr Drugs

Specialties Pediatrics
Pharmacology

Date 2012 Jun 19

PMID 22702743

Citations 4

Authors

Lesley J Scott

Natalie J Carter

Monique P Curran

Affiliations

Soon will be listed here.

Abstract

Live attenuated influenza vaccine (LAIV).[Fluenz™] has a convenient intranasal route of administration. In the EU, it is indicated for the prevention of influenza disease caused by the influenza virus strains contained in the vaccine in children and adolescents aged 2 years to <18 years. The vaccine elicits a high immunogenic response, is protective against seasonal influenza infection and is associated with the development of herd immunity. LAIV is generally well tolerated, with the safety of the vaccine in the approved pediatric population generally considered to be similar to that of placebo based on clinical trials and extensive experience involving more than 39 million vaccine doses.

Citing Articles

Emerging Role of Mucosal Vaccine in Preventing Infection with Avian Influenza A Viruses.

Wang T, Wei F, Liu J Viruses. 2020; 12(8).

PMID: 32784697 PMC: 7472103. DOI: 10.3390/v12080862.

Increased Immune Response Variability during Simultaneous Viral Coinfection Leads to Unpredictability in CD8 T Cell Immunity and Pathogenesis.

Kenney L, Cornberg M, Chen A, Emonet S, de la Torre J, Selin L J Virol. 2015; 89(21):10786-801.

PMID: 26269191 PMC: 4621125. DOI: 10.1128/JVI.01432-15.

Recombinant influenza virus carrying the conserved domain of respiratory syncytial virus (RSV) G protein confers protection against RSV without inflammatory disease.

Lee Y, Hwang H, Kim M, Lee Y, Cho M, Kwon Y Virology. 2015; 476:217-225.

PMID: 25553517 PMC: 4323758. DOI: 10.1016/j.virol.2014.12.004.

Bolstering Components of the Immune Response Compromised by Prior Exposure to Adenovirus: Guided Formulation Development for a Nasal Ebola Vaccine.

Choi J, Schafer S, Freiberg A, Croyle M Mol Pharm. 2015; 12(8):2697-711.

PMID: 25549696 PMC: 4525322. DOI: 10.1021/mp5006454.

References

He X, Holmes T, Zhang C, Mahmood K, Kemble G, Lewis D . Cellular immune responses in children and adults receiving inactivated or live attenuated influenza vaccines. J Virol. 2006; 80(23):11756-66. PMC: 1642596. DOI: 10.1128/JVI.01460-06. View

Ambrose C, Levin M, Belshe R . The relative efficacy of trivalent live attenuated and inactivated influenza vaccines in children and adults. Influenza Other Respir Viruses. 2011; 5(2):67-75. PMC: 3151550. DOI: 10.1111/j.1750-2659.2010.00183.x. View

Belshe R, Gruber W, Mendelman P, Mehta H, Mahmood K, Reisinger K . Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. J Infect Dis. 2000; 181(3):1133-7. DOI: 10.1086/315323. View

Bernstein D, Yan L, Treanor J, Mendelman P, Belshe R . Effect of yearly vaccinations with live, attenuated, cold-adapted, trivalent, intranasal influenza vaccines on antibody responses in children. Pediatr Infect Dis J. 2003; 22(1):28-34. DOI: 10.1097/00006454-200301000-00010. View

Ashkenazi S, Vertruyen A, Aristegui J, Esposito S, McKeith D, Klemola T . Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections. Pediatr Infect Dis J. 2006; 25(10):870-9. DOI: 10.1097/01.inf.0000237829.66310.85. View

Lum L, Borja-Tabora C, Breiman R, Vesikari T, Sablan B, Chay O . Influenza vaccine concurrently administered with a combination measles, mumps, and rubella vaccine to young children. Vaccine. 2009; 28(6):1566-74. DOI: 10.1016/j.vaccine.2009.11.054. View

Forrest B, Pride M, Dunning A, Capeding M, Chotpitayasunondh T, Tam J . Correlation of cellular immune responses with protection against culture-confirmed influenza virus in young children. Clin Vaccine Immunol. 2008; 15(7):1042-53. PMC: 2446637. DOI: 10.1128/CVI.00397-07. View

Vesikari T, Karvonen A, Korhonen T, Edelman K, Vainionpaa R, Salmi A . A randomized, double-blind study of the safety, transmissibility and phenotypic and genotypic stability of cold-adapted influenza virus vaccine. Pediatr Infect Dis J. 2006; 25(7):590-5. DOI: 10.1097/01.inf.0000220229.51531.47. View

Belshe R, Mendelman P, Treanor J, King J, Gruber W, Piedra P . The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N Engl J Med. 1998; 338(20):1405-12. DOI: 10.1056/NEJM199805143382002. View

10.

Davis M, King Jr J, Moag L, Cummings G, Magder L . Countywide school-based influenza immunization: direct and indirect impact on student absenteeism. Pediatrics. 2008; 122(1):e260-5. DOI: 10.1542/peds.2007-2963. View

11.

Belshe R, Gruber W . Prevention of otitis media in children with live attenuated influenza vaccine given intranasally. Pediatr Infect Dis J. 2000; 19(5 Suppl):S66-71. DOI: 10.1097/00006454-200005001-00010. View

12.

Glezen W, Gaglani M, Kozinetz C, Piedra P . Direct and indirect effectiveness of influenza vaccination delivered to children at school preceding an epidemic caused by 3 new influenza virus variants. J Infect Dis. 2010; 202(11):1626-33. PMC: 2974041. DOI: 10.1086/657089. View

13.

Vesikari T, Fleming D, Aristegui J, Vertruyen A, Ashkenazi S, Rappaport R . Safety, efficacy, and effectiveness of cold-adapted influenza vaccine-trivalent against community-acquired, culture-confirmed influenza in young children attending day care. Pediatrics. 2006; 118(6):2298-312. DOI: 10.1542/peds.2006-0725. View

14.

Carter N, Curran M . Live attenuated influenza vaccine (FluMist®; Fluenz™): a review of its use in the prevention of seasonal influenza in children and adults. Drugs. 2011; 71(12):1591-622. DOI: 10.2165/11206860-000000000-00000. View

15.

Breiman R, Brooks W, Goswami D, Lagos R, Borja-Tabora C, Lanata C . A multinational, randomized, placebo-controlled trial to assess the immunogenicity, safety, and tolerability of live attenuated influenza vaccine coadministered with oral poliovirus vaccine in healthy young children. Vaccine. 2009; 27(40):5472-9. DOI: 10.1016/j.vaccine.2009.07.002. View

16.

Fleming D, Crovari P, Wahn U, Klemola T, Schlesinger Y, Langussis A . Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma. Pediatr Infect Dis J. 2006; 25(10):860-9. DOI: 10.1097/01.inf.0000237797.14283.cf. View

17.

King Jr J, Stoddard J, Gaglani M, Moore K, Magder L, McClure E . Effectiveness of school-based influenza vaccination. N Engl J Med. 2006; 355(24):2523-32. DOI: 10.1056/NEJMoa055414. View

18.

Nolan T, Bernstein D, Block S, Hilty M, Keyserling H, Marchant C . Safety and immunogenicity of concurrent administration of live attenuated influenza vaccine with measles-mumps-rubella and varicella vaccines to infants 12 to 15 months of age. Pediatrics. 2008; 121(3):508-16. DOI: 10.1542/peds.2007-1064. View

19.

Belshe R, Ambrose C, Yi T . Safety and efficacy of live attenuated influenza vaccine in children 2-7 years of age. Vaccine. 2008; 26 Suppl 4:D10-6. DOI: 10.1016/j.vaccine.2008.06.083. View

20.

Ambrose C, Yi T, Falloon J . An integrated, multistudy analysis of the safety of Ann Arbor strain live attenuated influenza vaccine in children aged 2-17 years. Influenza Other Respir Viruses. 2011; 5(6):389-97. PMC: 3256242. DOI: 10.1111/j.1750-2659.2011.00243.x. View